Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 153 results found. Search for [ Mylan ]

Results 1 to 21 of 153
E Kumar Sharma
January 18, 2019
Globally, the number of diabetes patients is at around half a billion with over 30 million in the US alone, the most sought after market for diabetes care companies, especially those into insulin.


PB Jayakumar
New Delhi, January 9, 2019
Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide


PB Jayakumar
December 19, 2018
Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.


PTI
December 19, 2018



PTI
December 19, 2018



PTI
December 14, 2018



PTI
December 14, 2018



BusinessToday.In
December 12, 2018
The stock fell 5.16% intra day to 2569 level on the BSE. The large cap stock has fallen after two days of consecutive gain. On NSE, the stock fell 5.45% to 2,568 level. The stock was the top loser on Nifty.


PTI
November 30, 2018



PTI
November 30, 2018



PTI
November 26, 2018



PB Jayakumar
New Delhi, November 26, 2018
Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.


E Kumar Sharma
New Delhi, November 26, 2018
Teva, Mylan, and even India's biggest, Sun Pharma, are opting out of products that aren't commercially viable.


E Kumar Sharma
New Delhi, November 21, 2018
Some of the leading Indian pharma companies are pitching in to cater to the markets that some of the big pharma companies are vacating as part of their product optimisation strategies.


BusinessToday.In
November 21, 2018
Suboxone is British drugmaker Indivior's best-selling opioid addiction treatment drug in the US. Shares of Indivior tanked about 47 percent on Tuesday, in a record single-day fall. Jefferies analysts said they consider the ruling to be near-term positive, and one that allows the company to immediately re-launch the product, but still at-risk.


E. Kumar Sharma
New Delhi, October 29, 2018
Strides Pharma Science attributes its underwhelming performance to a confluence of headwinds and execution challenges.


E Kumar Sharma
New Delhi, October 25, 2018
Kiran Mazumdar-Shaw said Biocon delivered a strong revenue growth of 35 per cent this quarter, driven by robust performance across our biologics, small molecules and research services segments.


PTI
October 22, 2018



BusinessToday.In
October 15, 2018
The Natco Pharma stock closed 5.57% or 37 points higher at 717.05 on the BSE. The stock has been gaining for the last two days and has risen 8.36% during the period. The stock hit an intra day high of 733.70 (8.02%) in trade today.


PTI
October 15, 2018



PAGES 1 OF 8  12345